Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577265 | 0.85 | PDE10A (0.45) | CASP1TSHRALDH1A1CYP3A4MEN1 | |
| SCHEMBL1708822 | 0.82 | KMT2A (0.57) | CASP1ALDH1A1CYP3A4RECQLMEN1 | |
| SCHEMBL17774838 | 0.81 | KDM4E (0.60) | CASP1TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL7225379 | 0.80 | HPGD (0.49) | CASP1TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL10389402 | 0.80 | MEN1 (0.50) | TSHRALDH1A1MEN1KMT2APOLB | |
| SCHEMBL17774831 | 0.79 | GAA (0.49) | CASP1TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL10325047 | 0.79 | ALDH1A1 (0.46) | CASP1ALDH1A1CYP3A4RECQLMEN1 | |
| SCHEMBL5906549 | 0.79 | AR (0.47) | CASP1ALDH1A1CYP3A4RECQLMEN1 | |
| SCHEMBL4020512 | 0.79 | ALDH1A1 (0.64) | CASP1TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL24941116 | 0.78 | PDK2 (0.45) | ALDH1A1CYP3A4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2099765-B1 | 5, 6, OR 7-SUBSTITUTED-3-ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1724262-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2099765-A2 | 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | Rexahn Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008063548-A2 | 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS | REXAHN PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-4942163-A | LEUKEMIA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-07-17 | — | — | US | disclosed |
| US-4031073-A | Monoazo pigments containing barbituric acid or thio- or imino-derivatives thereof | CIBA-GEIGY CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | CASP1 4327/4885TSHR 3704/4885ALDH1A1 997/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | CASP1 4327/4885TSHR 3704/4885ALDH1A1 997/4885 |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | CASP1 16/4885TSHR 4307/4885ALDH1A1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.